Rajiv Jalan
@rajivjalan.bsky.social
Passionate about finding new solutions for patients with advanced liver disease. Doctor, scientist, teacher, entrepreneur, author….
Fantastic paper attempting to bring two Groups of Cirrhosis Leadership together — Baveno / EFCLIF.. portal hypertension meets systemic inflammation. Must say this is an amazing paper. Looking forward to your thoughts…
Pathomechanistic #Phenotypes of #Cirrhosis
Dalila Costa🇵🇹 Jonel Trebicka🇩🇪 Cristina Ripoll🇪🇸 Richard Moreau🇫🇷 @rajivjalan.bsky.social🇬🇧 Reiberger🇦🇹
📈 Portal Hypertension #PH & 🔥 Inflammation #SI coexist in pts w/ cirrhosis
💡review on PH-SI interplay in distinct cirrhosis stages
@easlnews.bsky.social
Dalila Costa🇵🇹 Jonel Trebicka🇩🇪 Cristina Ripoll🇪🇸 Richard Moreau🇫🇷 @rajivjalan.bsky.social🇬🇧 Reiberger🇦🇹
📈 Portal Hypertension #PH & 🔥 Inflammation #SI coexist in pts w/ cirrhosis
💡review on PH-SI interplay in distinct cirrhosis stages
@easlnews.bsky.social
New online! Interaction of inflammation and portal hypertension in cirrhosis progression
October 1, 2025 at 4:52 PM
Fantastic paper attempting to bring two Groups of Cirrhosis Leadership together — Baveno / EFCLIF.. portal hypertension meets systemic inflammation. Must say this is an amazing paper. Looking forward to your thoughts…
Reposted by Rajiv Jalan
Pathomechanistic #Phenotypes of #Cirrhosis
Dalila Costa🇵🇹 Jonel Trebicka🇩🇪 Cristina Ripoll🇪🇸 Richard Moreau🇫🇷 @rajivjalan.bsky.social🇬🇧 Reiberger🇦🇹
📈 Portal Hypertension #PH & 🔥 Inflammation #SI coexist in pts w/ cirrhosis
💡review on PH-SI interplay in distinct cirrhosis stages
@easlnews.bsky.social
Dalila Costa🇵🇹 Jonel Trebicka🇩🇪 Cristina Ripoll🇪🇸 Richard Moreau🇫🇷 @rajivjalan.bsky.social🇬🇧 Reiberger🇦🇹
📈 Portal Hypertension #PH & 🔥 Inflammation #SI coexist in pts w/ cirrhosis
💡review on PH-SI interplay in distinct cirrhosis stages
@easlnews.bsky.social
New online! Interaction of inflammation and portal hypertension in cirrhosis progression
Interaction of inflammation and portal hypertension in cirrhosis progression
Nature Reviews Gastroenterology & Hepatology, Published online: 29 September 2025; doi:10.1038/s41575-025-01107-2Portal hypertension and systemic inflammation are key factors driving decompensation and organ failure in cirrhosis. This Review examines those two factors and, based on their mechanistic interaction, proposes a new concept of the clinical phenotypes in decompensated cirrhosis.
www.nature.com
September 30, 2025 at 7:06 AM
Pathomechanistic #Phenotypes of #Cirrhosis
Dalila Costa🇵🇹 Jonel Trebicka🇩🇪 Cristina Ripoll🇪🇸 Richard Moreau🇫🇷 @rajivjalan.bsky.social🇬🇧 Reiberger🇦🇹
📈 Portal Hypertension #PH & 🔥 Inflammation #SI coexist in pts w/ cirrhosis
💡review on PH-SI interplay in distinct cirrhosis stages
@easlnews.bsky.social
Dalila Costa🇵🇹 Jonel Trebicka🇩🇪 Cristina Ripoll🇪🇸 Richard Moreau🇫🇷 @rajivjalan.bsky.social🇬🇧 Reiberger🇦🇹
📈 Portal Hypertension #PH & 🔥 Inflammation #SI coexist in pts w/ cirrhosis
💡review on PH-SI interplay in distinct cirrhosis stages
@easlnews.bsky.social
Reposted by Rajiv Jalan
Our @GeorgKRAMER myself & @CristinaRIPOLL perspective on staging of #Decompensated #Cirrhosis
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal
September 28, 2025 at 7:14 PM
Our @GeorgKRAMER myself & @CristinaRIPOLL perspective on staging of #Decompensated #Cirrhosis
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal
- this was a Letter ✉️ to @jhepatology.bsky.social in response to an article by Dr. Verma @rajivjalan.bsky.social et al
#NonAcuteDecompensation (NAD) 🔗 t.ly/mc4VG
- who responded w/ an interesting proposal
Reposted by Rajiv Jalan
Feel free to follow the new A-TANGO Consortium + #hepatology Starter Pack go.bsky.app/Tc8YSWq
#LiverSky #LiverResearch #LiverDisease #hepatitis #cirrhosis #ACLF #HepatologyJournals
@rajivjalan.bsky.social
@europeliver.bsky.social
@easlnews.bsky.social
@jhepatology.bsky.social
@ebtapper.bsky.social
#LiverSky #LiverResearch #LiverDisease #hepatitis #cirrhosis #ACLF #HepatologyJournals
@rajivjalan.bsky.social
@europeliver.bsky.social
@easlnews.bsky.social
@jhepatology.bsky.social
@ebtapper.bsky.social
April 25, 2025 at 9:38 PM
Feel free to follow the new A-TANGO Consortium + #hepatology Starter Pack go.bsky.app/Tc8YSWq
#LiverSky #LiverResearch #LiverDisease #hepatitis #cirrhosis #ACLF #HepatologyJournals
@rajivjalan.bsky.social
@europeliver.bsky.social
@easlnews.bsky.social
@jhepatology.bsky.social
@ebtapper.bsky.social
#LiverSky #LiverResearch #LiverDisease #hepatitis #cirrhosis #ACLF #HepatologyJournals
@rajivjalan.bsky.social
@europeliver.bsky.social
@easlnews.bsky.social
@jhepatology.bsky.social
@ebtapper.bsky.social
Reposted by Rajiv Jalan
High ammonia levels kill liver cells by damaging their mitochondria, but this can be prevented using an existing drug due to start clinical trials, finds a new study in mice led by Prof Rajiv Jalan @rajivjalan.bsky.social from UCL Division of Medicine
www.ucl.ac.uk/news/2025/ma...
www.ucl.ac.uk/news/2025/ma...
Ammonia build-up kills liver cells but can be prevented using existing drug
High levels of ammonia kill liver cells by damaging the mitochondria that power the cells. But this can be prevented using an existing drug due to start clinical trials, finds a new study in mice led ...
www.ucl.ac.uk
March 10, 2025 at 4:11 PM
High ammonia levels kill liver cells by damaging their mitochondria, but this can be prevented using an existing drug due to start clinical trials, finds a new study in mice led by Prof Rajiv Jalan @rajivjalan.bsky.social from UCL Division of Medicine
www.ucl.ac.uk/news/2025/ma...
www.ucl.ac.uk/news/2025/ma...
Reposted by Rajiv Jalan
🚨 New Insights in Cirrhosis! 🚨
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
March 7, 2025 at 4:09 PM
🚨 New Insights in Cirrhosis! 🚨
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
Please share your views about whether the PSVD nomenclature is the way forward or an oversimplification. Personally, I think it is an advance but hugely respect the view of #Lohse, #Sarin and #Kamath
Fascinating discussion on PSVD, NCPF, Idiopathic portal hypertension ongoing in @jhepatology.bsky.social @valdig.bsky.social @ebtapper.bsky.social would be worth a skytutorial
February 22, 2025 at 2:29 PM
Reposted by Rajiv Jalan
Fascinating discussion on PSVD, NCPF, Idiopathic portal hypertension ongoing in @jhepatology.bsky.social @valdig.bsky.social @ebtapper.bsky.social would be worth a skytutorial
February 22, 2025 at 2:15 PM
Fascinating discussion on PSVD, NCPF, Idiopathic portal hypertension ongoing in @jhepatology.bsky.social @valdig.bsky.social @ebtapper.bsky.social would be worth a skytutorial
Fascinating discussion on PSVD, NCPF, Idiopathic portal hypertension ongoing in @jhepatology.bsky.social @valdig.bsky.social @ebtapper.bsky.social would be worth a skytutorial
February 22, 2025 at 2:15 PM
Fascinating discussion on PSVD, NCPF, Idiopathic portal hypertension ongoing in @jhepatology.bsky.social @valdig.bsky.social @ebtapper.bsky.social would be worth a skytutorial
Reposted by Rajiv Jalan
Hello!
I’m here to celebrate all you and your colleagues do for us patients!
Yay!! Welcome!!
I’m here to celebrate all you and your colleagues do for us patients!
Yay!! Welcome!!
February 20, 2025 at 2:51 PM
Hello!
I’m here to celebrate all you and your colleagues do for us patients!
Yay!! Welcome!!
I’m here to celebrate all you and your colleagues do for us patients!
Yay!! Welcome!!
Thanks for following Elliot… good to be here and getting out of X
We are on our second starter pack for GI / Hepatology
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR
#medsky #GIsky #LiverSky
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR
#medsky #GIsky #LiverSky
February 20, 2025 at 1:16 PM
Thanks for following Elliot… good to be here and getting out of X
Reposted by Rajiv Jalan
We are on our second starter pack for GI / Hepatology
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR
#medsky #GIsky #LiverSky
Part 1: go.bsky.app/8Pho2tp
Part 2: go.bsky.app/VGyLKjR
#medsky #GIsky #LiverSky
February 20, 2025 at 1:13 PM
Hello, Liver People on Blue SKy… migrating from X…#liver twitter, @uclnews.bsky.social
February 20, 2025 at 12:33 PM
Hello, Liver People on Blue SKy… migrating from X…#liver twitter, @uclnews.bsky.social